Who ChondroFiller injection is suitable for

The first question worth answering is whether your joint is the right kind of damaged — because ChondroFiller injection is designed for a specific pattern of cartilage loss, not every form of joint wear.

The treatment is indicated for Grade III or IV focal articular cartilage defects: areas where cartilage has thinned severely or broken down entirely within a contained patch, while the surrounding joint surface remains comparatively intact. Where cartilage loss is patchy and contained, the injectable collagen scaffold has a defined space to occupy and a population of the patient's own progenitor cells to recruit. That repair biology does not apply to joints where degeneration has spread diffusely across multiple surfaces — patients with widespread, end-stage osteoarthritis fall outside the criteria for this pathway.

Defect size is a further consideration. Each box of ChondroFiller covers lesions up to approximately 3 cm², and in some cases two boxes can extend that to 6 cm², making it relevant for a range of focal injuries and post-traumatic lesions rather than only small, incidental defects.

Eligible joints span the full musculoskeletal range: knee, hip, ankle, shoulder, elbow, wrist, thumb, and smaller hand joints, as well as the temporomandibular joint. The injection is not confined to the knee, despite that being the joint most commonly discussed in cartilage-repair literature.

For patients who do qualify, published clinical evidence suggests that 70–85% achieve meaningful symptom relief at three to five years, with IKDC scores improving by approximately 30 points in knee studies — a useful benchmark when weighing this route against surgical alternatives.

Where ChondroFiller injection is available in the UK

Certified access to ChondroFiller injection in the UK is currently concentrated in London, and the market is at an early stage.

London Cartilage Clinic, based at 66 Harley Street, was the first UK clinic to offer the treatment and remains the primary certified centre. Professor Paul Y.F. Lee leads delivery there. A second named provider, AMSK Clinic, also routinely assesses and treats patients. Beyond these two London practices, no further certified UK centres have been confirmed.

For patients based outside the capital — whether in England, Scotland, Wales, or Northern Ireland — travelling to London is currently the only route to in-person treatment. That said, both centres offer remote initial consultations, which means suitability can be assessed without an immediate trip to Harley Street. A remote assessment is a practical first step: it establishes whether the joint qualifies, clarifies how many boxes would be needed, and avoids unnecessary travel for patients who may not meet the clinical criteria.

The absence of regional options reflects where the UK market sits right now, not a limitation of the procedure itself. Patients who do qualify and travel for treatment find the procedure is completed as a single outpatient appointment — so the geographic inconvenience is, in most cases, a one-off commitment rather than a recurring one.

What the procedure actually involves

The procedure itself takes around 30–45 minutes and requires no theatre booking, no general anaesthetic, and no surgical incision. Under continuous ultrasound guidance, the ChondroFiller injectable collagen scaffold is delivered directly into the defect site as an outpatient appointment — patients return home the same day.

Once placed, the scaffold self-polymerises into a stable hydrogel within approximately three to five minutes. That gel occupies the defect and acts as a biological signal, drawing the patient's own progenitor cells into the site and prompting them to mature into cartilage-forming cells — a process called matrix-induced chondrogenesis. No donor cells are introduced; the repair material comes entirely from the patient's own tissue.

The single-stage, no-anaesthetic design has a direct bearing on what the procedure costs. There is no anaesthetist fee, no theatre time, no inpatient bed, and no recovery ward. Surgical cartilage repair — ACI, MACI, or OATS — routinely involves all of those, which is why private surgical quotes across UK clinics typically run to £7,000–£14,000.

What ChondroFiller injection costs in the UK

Pricing follows a fixed three-tier structure based on the number of boxes required:

• One box — £3,000
• Two boxes — £5,500
• Three boxes — £8,000

The number of boxes is determined at the pre-procedure imaging review, once the defect dimensions are confirmed on MRI. Most patients presenting with a single focal defect need only one box, so the £3,000 tier covers the majority of cases.

Each quoted figure is all-inclusive. The fee covers the initial consultation, pre-procedure imaging review, real-time ultrasound guidance on the day, the ChondroFiller injectable collagen scaffold itself, intravenous antibiotic cover, and a six-week follow-up appointment. There are no separately billed day-of charges — the figure patients see when they enquire is the figure they pay.

For larger or multi-compartment joints such as the hip or shoulder, an approximate range of £6,500–£9,500 has been cited by specialist sources. This is less consistently published than the knee-focused tiers above, and patients seeking hip or shoulder treatment should confirm the exact figure directly with the treating clinic at assessment, as it will depend on defect size and joint complexity.

Combination packages

For patients with more advanced joint disease — typically KL Grade III or IV osteoarthritis — a combination approach is available. ChondroFiller injection, as the regenerative scaffold pathway, can be used alongside Arthrosamid, a non-regenerative polyacrylamide hydrogel that addresses a different aspect of the joint environment. The two products work by distinct mechanisms and are not interchangeable; used together, they target separate roles. This combined package is priced at £6,000. A further option, the Tri-Active package, adds autologous mesenchymal stem cell therapy to bring the total to £11,000.

These prices sit in a different category from surgical cartilage repair — which, as described in the previous section, involves general anaesthesia, theatre time, and significantly higher associated fees. For patients considering their options, the outpatient, no-anaesthetic nature of ChondroFiller injection is directly reflected in the cost structure.

Private insurance and the NHS

ChondroFiller injection sits entirely outside NHS provision. There is no commissioning decision, no active pilot programme, and no public-funding application currently under way. For patients hoping that might change soon, the honest position is that none is expected in the near term.

The distinction between regulatory approval and NHS access is worth understanding. ChondroFiller holds CE Class III designation as a medical device — the highest regulatory tier, requiring substantial clinical evidence — but CE marking and NHS commissioning are entirely separate processes. A device can be fully approved for safe clinical use and still sit outside the NHS funding framework indefinitely. ACI (autologous chondrocyte implantation) illustrates what commissioned access looks like: the NHS funds it at a small number of specialist centres following a formal commissioning review. ChondroFiller has not gone through an equivalent route, and that gap defines the current access reality.

Private medical insurance

Coverage through private medical insurance is possible, but not guaranteed, and patients should not assume approval before checking. The procedure is billed using CCSD codes W3111 (cartilage regeneration with collagen scaffold) and W8500, which appear on the fee schedules of several UK insurers. Approvals are most commonly reported through Bupa, Aviva, and WPA.

That said, individual policy terms vary considerably, and a positive outcome for one patient does not predict another's. Written pre-authorisation — obtained before the procedure date, not retrospectively — is essential. The guidance above reflects insurer positions as of October 2025; insurer coverage decisions change, and any patient exploring this route should confirm their position directly with their provider before proceeding.

How to arrange an assessment

Booking starts at londoncartilage.com. The London Cartilage Clinic offers an initial remote assessment, which allows patients to discuss their imaging and clinical history with the team before travelling to Harley Street — a practical first step for anyone based outside London, or for those who want to confirm suitability before committing to an in-person visit. If existing MRI scans are available, sharing them ahead of this conversation helps the clinical team advise on next steps more efficiently and assess whether the defect is likely to meet the criteria for treatment. Once suitability is established, an in-person appointment at the clinic can be arranged for the ChondroFiller injection itself.